Why do two stimulant families differ? MN660's Unit 7 comparison answers at the transporter, where methylphenidate blocks reuptake and amphetamine reverses it, then follows the consequences into clearance. Searches like "mn 660 unit 7 assignment example", "mn660 unit 7 sample" and "mn660 unit 7 example" land here.
What a finished MN660 Unit 7 drug class comparison looks like
A comparison table precedes four analytic paragraphs. Rows cover the molecular target, the mechanism at that target, whether the effect depends on neuronal firing, vesicular effects, metabolism, and the resulting interaction profile. Methylphenidate binds the dopamine and norepinephrine transporters and blocks reuptake, so it amplifies dopamine that neurons release on their own. Amphetamine is carried into the terminal as a transporter substrate, disrupts VMAT2 storage and drives the transporter in reverse, releasing dopamine whether or not the neuron fires, with TAAR1 agonism contributing. Metabolism diverges as well: carboxylesterase 1 hydrolyzes methylphenidate to ritalinic acid, while amphetamine is partly cleared by CYP2D6 and excreted in urine at a rate that urinary pH alters. Lisdexamfetamine appears as a prodrug whose conversion in blood limits how fast d-amphetamine emerges.
How a MN660 Unit 7 example is structured
The opening paragraph names the basis of comparison, mechanism at the transporter, and explains why the shared label hides it. The table follows with references for each cell, since transporter pharmacology is where textbook summaries most often simplify. Four paragraphs then take cross-cutting questions rather than one drug at a time. What happens at the transporter, and does the effect need an active neuron? What changes inside the vesicle? How is each family cleared, and which enzyme or physiological variable alters that clearance? What does the mechanism predict about misuse potential and speed of onset? Each paragraph ends by naming one observable consequence. A closing paragraph states limits: individual response varies, human transporter data are partial, and the comparison concerns mechanism rather than which family suits a given patient, a question left to prescribing coursework.
One difference carried throughout
Reuptake blockade against reversed transport is established in the introduction and then used in every later paragraph. Onset, firing dependence and misuse potential each trace back to it rather than arriving as separate facts.
Questions that cut across both
The analysis is organized by question, not by drug, so each paragraph compares directly. Describing the two families in separate halves would only restate the table in prose and lose the comparison itself.
Release without a signal
Because amphetamine can push dopamine out regardless of firing, its effect depends less on ongoing neuronal activity. The comparison treats this as the mechanistic core of the difference, not as a matter of potency.
Clearance by different routes
Carboxylesterase 1 handles methylphenidate; CYP2D6 and pH-sensitive renal excretion handle amphetamine. The paper notes that urinary acidifiers and alkalinizers change amphetamine exposure, a property methylphenidate does not share.
A prodrug as a rate limit
Lisdexamfetamine's conversion by red blood cell enzymes caps how quickly d-amphetamine appears. The comparison presents this as a pharmacokinetic design with mechanistic consequences and cites the label for where conversion happens.
Where marks go in MN660 Unit 7
Comparisons here score lowest when they describe two stimulant families in parallel columns and never say how they differ at the transporter, the single fact the unit is built around. Calling both simply dopamine reuptake inhibitors is the factual error seen most and draws a correction almost everywhere. Graders mark down the firing-dependence point when it is stated without explanation, since the reason, reversed transport, is what shows understanding. Metabolism is often thin: CYP enzymes assigned to methylphenidate, or urinary pH left out of amphetamine elimination. Misuse potential attributed to potency alone, rather than to rate of rise and release mechanism, is judged incomplete. Any sentence ranking the families for a type of patient, or naming amounts, costs credit for shifting from pharmacology to choice. Small deductions follow from brand names given without generics.
Get a MN660 Unit 7 example written to your instructions
Which two families does the Unit 7 prompt in your MN660 section place next to each other? Send them, plus the rubric and any table requirement. A free first comparison is written to those instructions within 24-48h, organized by question rather than by drug, with every difference traced to the mechanism producing it and every table cell sourced.
MN660 Unit 7 questions, answered
Is methylphenidate really not a releaser?
At clinical concentrations it acts mainly as a reuptake blocker at the dopamine and norepinephrine transporters, which is the standard account in pharmacology references. Some research explores additional actions, but the blocker-versus-releaser distinction remains the accepted basis for comparing it with amphetamine. If your sources describe nuances, cite them and present the distinction as the main difference rather than an absolute one.
Should the comparison include non-stimulants such as atomoxetine?
Only when the prompt names them, since a third family changes the assignment. Atomoxetine inhibits the norepinephrine transporter without the dopamine release profile of either stimulant family, and treating it well takes space. When the prompt sets two stimulant families side by side, keep the focus there and mention non-stimulants in a single sentence at most.
How detailed should the metabolism section be?
Detailed enough to predict interactions. Naming carboxylesterase 1 for methylphenidate and CYP2D6 plus urinary pH for amphetamine lets a reader foresee which co-medications or conditions matter. Enzyme lists without consequences read as memorization; one sentence per family explaining what would raise or lower exposure usually counts for more than a longer list of pathways.